CRISPR Therapeutic Development Services
FromSynthego
For CRISPR-based therapies, understanding the potential and actual off-target edits associated with your CRISPR drug components is critical to their safety and efficacy. Synthego has partnered with SeQure Dx, a leading off-target editing analysis company, to bring you best-in-class OTE analysis for your RUO-to-GMP gRNAs. Whether you are deciding among several gRNAs, characterizing your final gRNA, or filing your IND, we have the method that's right for you.
Most popular related searches
The value of SeQure Dx platforms for your therapeutic development:
- Orthogonal nomination and confirmation methods that meet the latest regulatory guidelines for OTE analysis of CRISPR-based therapeutics
- Nomination and confirmation methods are nuclease-agnostic so you have the versatility to find the right solution for your therapeutic
- Accounts for population sequence variants from over 4000 genomes and can incorporate client-provided variant data into the predicted off-target identification process
- Customize your methods to fit your experiments